CN111789866A - 高分子型抗癌药的抗肿瘤效果的增强剂 - Google Patents

高分子型抗癌药的抗肿瘤效果的增强剂 Download PDF

Info

Publication number
CN111789866A
CN111789866A CN202010209784.4A CN202010209784A CN111789866A CN 111789866 A CN111789866 A CN 111789866A CN 202010209784 A CN202010209784 A CN 202010209784A CN 111789866 A CN111789866 A CN 111789866A
Authority
CN
China
Prior art keywords
anticancer drug
polymer
drug
apatite
enhancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010209784.4A
Other languages
English (en)
Chinese (zh)
Inventor
吴鑫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nano Surpass Co ltd
Original Assignee
Nano Surpass Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nano Surpass Co ltd filed Critical Nano Surpass Co ltd
Publication of CN111789866A publication Critical patent/CN111789866A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202010209784.4A 2019-04-04 2020-03-23 高分子型抗癌药的抗肿瘤效果的增强剂 Pending CN111789866A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019-072054 2019-04-04
JP2019072054A JP2020169146A (ja) 2019-04-04 2019-04-04 高分子型抗がん剤の抗腫瘍効果の増強剤

Publications (1)

Publication Number Publication Date
CN111789866A true CN111789866A (zh) 2020-10-20

Family

ID=72745700

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010209784.4A Pending CN111789866A (zh) 2019-04-04 2020-03-23 高分子型抗癌药的抗肿瘤效果的增强剂

Country Status (2)

Country Link
JP (1) JP2020169146A (ja)
CN (1) CN111789866A (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2765465C2 (ru) * 2021-04-28 2022-01-31 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) Способ функционализации кальцийфосфатного материала препаратом цисплатина в водном растворе

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2022071496A1 (ja) * 2020-09-30 2022-04-07

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140302145A1 (en) * 2012-11-28 2014-10-09 Toshihiro Akaike Pharmaceutical composition for treating cancer using carbonate apatite nanoparticles
JP2015155392A (ja) * 2014-02-20 2015-08-27 弘幸 中西 グルコースと炭酸アパタイトを使用した抗癌剤
US20170128487A1 (en) * 2014-02-20 2017-05-11 Osaka University Enhancer of anti-tumor effect of anti-cancer agent

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017259576B2 (en) * 2016-05-06 2020-09-17 Biodynamic Research Foundation Polymerized drug-containing pharmaceutical composition

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140302145A1 (en) * 2012-11-28 2014-10-09 Toshihiro Akaike Pharmaceutical composition for treating cancer using carbonate apatite nanoparticles
JP2015155392A (ja) * 2014-02-20 2015-08-27 弘幸 中西 グルコースと炭酸アパタイトを使用した抗癌剤
US20170128487A1 (en) * 2014-02-20 2017-05-11 Osaka University Enhancer of anti-tumor effect of anti-cancer agent

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2765465C2 (ru) * 2021-04-28 2022-01-31 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) Способ функционализации кальцийфосфатного материала препаратом цисплатина в водном растворе

Also Published As

Publication number Publication date
JP2020169146A (ja) 2020-10-15

Similar Documents

Publication Publication Date Title
Li et al. Co-delivery of oxygen and erlotinib by aptamer-modified liposomal complexes to reverse hypoxia-induced drug resistance in lung cancer
Mu et al. Iron oxide nanoparticle targeted chemo-immunotherapy for triple negative breast cancer
Lu et al. Afatinib-loaded immunoliposomes functionalized with cetuximab: A novel strategy targeting the epidermal growth factor receptor for treatment of non-small-cell lung cancer
CA2913023C (en) Pharmaceutical composition, preparation and uses thereof
Xie et al. Challenges and opportunities from basic cancer biology for nanomedicine for targeted drug delivery
Ma et al. Enhanced immunotherapy of SM5-1 in hepatocellular carcinoma by conjugating with gold nanoparticles and its in vivo bioluminescence tomographic evaluation
JP5436650B1 (ja) スーパーアパタイト超微細ナノ粒子
Khesht et al. Blockade of CD73 using siRNA loaded chitosan lactate nanoparticles functionalized with TAT-hyaluronate enhances doxorubicin mediated cytotoxicity in cancer cells both in vitro and in vivo
Li et al. Albumin-stabilized layered double hydroxide nanoparticles synergized combination chemotherapy for colorectal cancer treatment
Gong et al. A nanodrug combining CD47 and sonodynamic therapy efficiently inhibits osteosarcoma deterioration
Zhang et al. Targeted micelles with chemotherapeutics and gene drugs to inhibit the G1/S and G2/M mitotic cycle of prostate cancer
CN111789866A (zh) 高分子型抗癌药的抗肿瘤效果的增强剂
Nakhjavani et al. Triple-negative breast cancer brain metastasis: An update on druggable targets, current clinical trials, and future treatment options
Liao et al. Nanomodified strategies to overcome EGFR-tyrosine kinase inhibitors resistance in non-small cell lung cancer
TW202237066A (zh) 藥物傳送用組成物、其製造方法及其用途
JP6516723B2 (ja) 抗癌剤の抗腫瘍効果の増強剤
Lajous et al. Hybrid Gd 3+/cisplatin cross-linked polymer nanoparticles enhance platinum accumulation and formation of DNA adducts in glioblastoma cell lines
Park et al. HER2-specific aptide conjugated magneto-nanoclusters for potential breast cancer imaging and therapy
US20220096382A1 (en) Polymersomes functionalised with multiple ligands
US8361510B2 (en) Nanogels for cellular delivery of therapeutics
Bahreyni et al. Engineering a facile and versatile nanoplatform to facilitate the delivery of multiple agents for targeted breast cancer chemo-immunotherapy
Zhou et al. Targeted delivery of glypican 3 (GPC3) antibody-modified microRNA (miR let-7b-5p) polymer nanoparticles to sorafenib-resistant hepatsocellular carcinoma cells
Liu et al. A dual-sensitive nanoparticle-mediated deepening synergistic therapy strategy involving DNA damage and ICD stimuli to treat triple-negative breast cancer
Xiao et al. Trojan-like peptide drug conjugate design and construction for application in treatment of triple-negative breast cancer
CN115768523A (zh) 纳米粒子、电离辐射及其创新治疗组合

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20201020